99 related articles for article (PubMed ID: 7915095)
1. Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions.
Pechoux C; Chardonnet Y; Noël P
Anticancer Res; 1994; 14(3B):1343-60. PubMed ID: 7915095
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1319-30. PubMed ID: 9137492
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of plasma prolactin in breast cancer: comparison with the expression of c erb B-2 oncoprotein.
Bhatavdekar JM; Patel DD; Sherbet GV; Giri DD; Karelia NH; Vora HH; Shah NG; Suthar TP; Nadkarni SP; Balar DB
Eur J Surg Oncol; 1993 Oct; 19(5):409-13. PubMed ID: 8104829
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression.
Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S
In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
[TBL] [Abstract][Full Text] [Related]
9. Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions.
Edorh A; Leroux A; N'sossani B; Parache RM; Rihn B
Cell Mol Biol (Noisy-le-grand); 1999 Sep; 45(6):831-40. PubMed ID: 10541479
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen].
Antunes A; Silva T; Godinho I; Amaral N; Oliveira C
Acta Med Port; 2004; 17(4):271-6. PubMed ID: 15941551
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases.
Battifora H; Gaffey M; Esteban J; Mehta P; Bailey A; Faucett C; Niland J
Mod Pathol; 1991 Jul; 4(4):466-74. PubMed ID: 1681535
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
13. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
14. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
16. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.
Gorgoulis VG; Barbatis C; Poulias I; Karameris AM
Mod Pathol; 1995 Sep; 8(7):758-64. PubMed ID: 8539234
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues.
Gullick WJ; Hughes CM; Mellon K; Neal DE; Lemoine NR
J Pathol; 1991 Aug; 164(4):285-9. PubMed ID: 1681040
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
Pechoux C; Chardonnet Y; Chignol MC; Noël P
Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]